Cancer Chemotherapy and Pharmacology

, Volume 63, Issue 6, pp 1157–1159 | Cite as

Extended survival of a HER-2-positive metastatic breast cancer patient with brain metastases also treated with intrathecal trastuzumab

  • Mariantonietta Colozza
  • Elisa Minenza
  • Stefania Gori
  • Daniela Fenocchio
  • Cristina Paolucci
  • Cynthia Aristei
  • Piero Floridi
Short Communication


Trastuzumab Brain Metastasis Capecitabine Lapatinib Metastatic Breast Cancer Patient 


  1. 1.
    Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER 2 for metastatic breast cancer that overexpresses HER 2. N Engl J Med 344:783–792PubMedCrossRefGoogle Scholar
  2. 2.
    Stemmler HJ, Schmitt M, Willems A et al (2007) Ratio of trastuzumab in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anti-Cancer Drug 18:23–28CrossRefGoogle Scholar
  3. 3.
    Geyer CE, Forster J, Lindquist D et al (2006) Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med 355:2733–2743PubMedCrossRefGoogle Scholar
  4. 4.
    Clayton AJ, Danson S, Jolly S et al (2004) Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 91:639–643PubMedGoogle Scholar
  5. 5.
    Gori S, Rimondini S, De Angelis V et al (2007) Central nervous system metastases in HER2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. The Oncologist 12:766–773PubMedCrossRefGoogle Scholar
  6. 6.
    Bendell JC, Domcheck SM, Burstein HJ et al (2003) Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972–2977PubMedCrossRefGoogle Scholar
  7. 7.
    Lai R, Dang CT, Malkin MG, Abrey LE (2004) The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 101:810–816PubMedCrossRefGoogle Scholar
  8. 8.
    Shmueli E, Wigler N, Inbar M (2004) Central nervous system progression among patients with metastatic breast cancer responding to trastuzumab treatment. Eur J Cancer 40:379–382PubMedCrossRefGoogle Scholar
  9. 9.
    Metro G, Sperduti I, Russillo M et al (2007) Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. Oncologist 12:1467–1469PubMedCrossRefGoogle Scholar
  10. 10.
    Gori S, De Angelis V, Colozza M et al (2007) In reply. Oncologist 12:1469–1471CrossRefGoogle Scholar
  11. 11.
    Grossi PM, Ochiai H, Archer GE et al (2003) Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res 9:5514–5520PubMedGoogle Scholar
  12. 12.
    Laufman LR, Forsthoefel KF (2001) Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2:235PubMedGoogle Scholar
  13. 13.
    Stemmler HJ, Schmitt M, Harbeck N et al (2006) Application of intrathecal trastuzumab (Herceptin trade mark) for treatment of meningeal carcinomatosis in HER 2 overexpressing metastatic breast cancer. Oncol Rep 15:1373–1377PubMedGoogle Scholar
  14. 14.
    Platini C, Long J, Walter S (2006) Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzumab. Lancet Oncol 7:778–780PubMedCrossRefGoogle Scholar
  15. 15.
    Stemmler HJ, Mengele K, Schmitt M et al (2008) Intrathecal trastuzumab (herceptin) and methotrexate for meningeal carcinomatosis in HER2 overexpressing metastatic breast cancer: a case report. Anticancer Drug 19:832–836CrossRefGoogle Scholar
  16. 16.
    Fouladi M, Chintagumpala M, Laningham FH et al (2006) White matter lesions detected by magnetic resonance imaging after radiotherapy in children with medulloblastoma or primitive neuroectodermal tumor. J Clin Oncol 22:4551–4560CrossRefGoogle Scholar
  17. 17.
    Gori S, Sidoni A, Colozza M et al (2007) EGFR, MAPK, and Akt status by immunohisochemistry (IHC) are not correlated with clinical outcome in HER-2 positive (HER2 +) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) with or without chemotherapy (CT). J Clin Oncol Suppl 25:54s (abstract 1090)Google Scholar
  18. 18.
    Nahta R, Yu D, Hung M-C et al (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3:269–280PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Mariantonietta Colozza
    • 1
  • Elisa Minenza
    • 1
  • Stefania Gori
    • 1
  • Daniela Fenocchio
    • 2
  • Cristina Paolucci
    • 3
  • Cynthia Aristei
    • 4
  • Piero Floridi
    • 5
  1. 1.S.C. OncologiaAzienda OspedalieraPerugiaItaly
  2. 2.Servizio di Anatomia PatologicaAzienda OspedalieraPerugiaItaly
  3. 3.Laboratorio Preparazione Farmaci AntiblasticiAzienda OspedalieraPerugiaItaly
  4. 4.Istituto di RadioterapiaAzienda OspedalieraPerugiaItaly
  5. 5.S.C. NeuroradiologiaAzienda OspedalieraPerugiaItaly

Personalised recommendations